New Treatment Approved for Osteoporosis With High Risk for Fracture
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
All articles by Steve Duffy
Sustained Response With Secukinumab in Axial Spondyloarthritis
Results showed that at Week 52, secukinumab was associated with a significant and clinically meaningful reduction in disease activity compared with placebo.
Rituximab Gains Expanded Approval in Pediatrics
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare diseases that are generally specific to the lungs, kidneys and upper airways.
- Loading...
Loading...
Next post in Vasculitis
Loading... 
Loading...